Anita K Dunbier
Overview
Explore the profile of Anita K Dunbier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McGuinness C, Black M, Dunbier A
Cancer Med
. 2023 Nov;
12(23):21545-21560.
PMID: 37974533
Background: Genome-wide measures of genetic disruption such as tumour mutation burden (TMB) and mutation signatures are emerging as useful biomarkers to stratify patients for treatment. Clinicians commonly use cancer gene...
2.
Hazlett J, Niemi V, Aiderus A, Powell K, Wise L, Kemp R, et al.
Breast Cancer Res
. 2021 Oct;
23(1):95.
PMID: 34602068
Background: Oestrogen receptor-positive (ER+) breast cancer is commonly treated using endocrine therapies such as aromatase inhibitors which block synthesis of oestradiol, but the influence of this therapy on the immune...
3.
McMillan H, Keeshan K, Dunbier A, Mace P
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34205360
The Tribbles family of proteins-comprising TRIB1, TRIB2, TRIB3 and more distantly related STK40-play important, but distinct, roles in differentiation, development and oncogenesis. Of the four Tribbles proteins, TRIB1 has been...
4.
Jamieson S, Ruan Z, Burgess A, Curry J, McMillan H, Brewster J, et al.
Sci Signal
. 2018 Sep;
11(549).
PMID: 30254053
The Tribbles family of pseudokinases recruits substrates to the ubiquitin ligase COP1 to facilitate ubiquitylation. CCAAT/enhancer-binding protein (C/EBP) family transcription factors are crucial Tribbles substrates in adipocyte and myeloid cell...
5.
Aiderus A, Black M, Dunbier A
BMC Cancer
. 2018 Aug;
18(1):805.
PMID: 30092766
Background: Altered cellular metabolism is a hallmark of cancer but the association between utilisation of particular metabolic pathways in tumours and patient outcome is poorly understood. We sought to investigate...
6.
Prat A, Lluch A, Turnbull A, Dunbier A, Calvo L, Albanell J, et al.
Clin Cancer Res
. 2016 Dec;
23(12):3035-3044.
PMID: 27903675
Hormone receptor-positive (HR) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified. Research-based PAM50 subtyping and expression of additional genes...
7.
Turnbull A, Arthur L, Renshaw L, Larionov A, Kay C, Dunbier A, et al.
J Clin Oncol
. 2015 Jun;
33(20):2270-8.
PMID: 26033813
Purpose: Aromatase inhibitors (AIs) have an established role in the treatment of breast cancer. Response rates are only 50% to 70% in the neoadjuvant setting and lower in advanced disease....
8.
Lopez-Knowles E, Wilkerson P, Ribas R, Anderson H, Mackay A, Ghazoui Z, et al.
Breast Cancer Res
. 2015 Apr;
17:35.
PMID: 25888249
Introduction: Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common. The aims of this study were...
9.
Patani N, Dunbier A, Anderson H, Ghazoui Z, Ribas R, Anderson E, et al.
Clin Cancer Res
. 2014 Jun;
20(15):3962-73.
PMID: 24916694
Purpose: Endocrine therapies include aromatase inhibitors and the selective estrogen receptor (ER) downregulator fulvestrant. This study aimed to determine whether the reported efficacy of fulvestrant over anastrozole, and high- over...
10.
Gao Q, Patani N, Dunbier A, Ghazoui Z, Zvelebil M, Martin L, et al.
Clin Cancer Res
. 2014 Mar;
20(9):2485-94.
PMID: 24634384
Purpose: To investigate potential associations between gene modules representing key biologic processes and response to aromatase inhibitors (AI) in estrogen receptor-positive (ER(+)) breast cancer. Patients And Methods: Paired gene expression...